Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2023 | ADCs for advanced UC and their molecular markers of response

Daniel Petrylak • 16 Feb 2023
GU Cancers 2023
Bladder Cancer Genitourinary Cancer Urothelial Carcinoma Antibodies Enfortumab vedotin Sacituzumab govitecan

Daniel P. Petrylak, MD, Yale Cancer Center, New Haven, CT, talks on antibody-drug conjugates (ADCs) for advanced urothelial carcinoma and the importance of understanding their associated molecular markers of response. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Daniel Petrylak

LuxAR-02: luxdegalutamide and 177Lu-PSMA-617 in pre-treated mCRPC
0:59
LuxAR-02: luxdegalutamide and 177Lu-PSMA-617 in pre-treated mCRPC
Daniel Petrylak • 27 Feb 2026
Enhancing toxicity management with EV-pembrolizumab in bladder cancer
0:46
Enhancing toxicity management with EV-pembrolizumab in bladder cancer
Daniel Petrylak • 27 Feb 2026
Improving first-line urothelial carcinoma care in community practice
1:12
Improving first-line urothelial carcinoma care in community practice
Daniel Petrylak • 27 Feb 2026
Initial results from Phase I/II Study of luxdegalutamide in mCRPC
1:07
Initial results from Phase I/II Study of luxdegalutamide in mCRPC
Daniel Petrylak • 31 May 2024

Related Videos

Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
1:55
Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
Sarah Howlett • 26 Oct 2026
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
2:20
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
Jens Bedke • 26 Oct 2026
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
2:24
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
Jens Bedke • 26 Oct 2026
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
2:58
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
Jens Bedke • 26 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals